Royce & Associates LP acquired a new position in shares of Diebold Nixdorf, Incorporated (NYSE:DBD – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 176,908 shares of the technology company’s stock, valued at approximately $7,901,000. Royce & Associates LP owned approximately 0.47% of Diebold Nixdorf as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the stock. Amalgamated Bank bought a new stake in shares of Diebold Nixdorf during the second quarter worth $34,000. nVerses Capital LLC bought a new stake in Diebold Nixdorf during the 2nd quarter worth about $35,000. ClariVest Asset Management LLC boosted its stake in shares of Diebold Nixdorf by 1.7% during the 2nd quarter. ClariVest Asset Management LLC now owns 64,874 shares of the technology company’s stock worth $2,496,000 after buying an additional 1,067 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Diebold Nixdorf by 215.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,770 shares of the technology company’s stock valued at $145,000 after acquiring an additional 2,576 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Diebold Nixdorf in the first quarter valued at about $105,000. Institutional investors own 97.04% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on DBD. StockNews.com lowered Diebold Nixdorf from a “buy” rating to a “hold” rating in a research report on Friday, October 11th. Wedbush reiterated an “outperform” rating and issued a $50.00 price target on shares of Diebold Nixdorf in a research note on Monday, November 4th. Finally, DA Davidson boosted their price objective on shares of Diebold Nixdorf from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, August 9th.
Diebold Nixdorf Stock Up 3.8 %
DBD opened at $40.58 on Monday. The stock’s fifty day simple moving average is $44.10 and its 200 day simple moving average is $42.03. Diebold Nixdorf, Incorporated has a 1-year low of $22.66 and a 1-year high of $51.81. The stock has a market cap of $1.52 billion, a PE ratio of 312.18 and a beta of 2.15. The company has a current ratio of 1.45, a quick ratio of 0.96 and a debt-to-equity ratio of 1.02.
Insider Activity
In other news, EVP Frank Tobias Baur bought 1,150 shares of the stock in a transaction dated Tuesday, August 27th. The shares were bought at an average price of $40.58 per share, for a total transaction of $46,667.00. Following the completion of the purchase, the executive vice president now owns 24,262 shares in the company, valued at approximately $984,551.96. This trade represents a 4.98 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.04% of the company’s stock.
Diebold Nixdorf Company Profile
Diebold Nixdorf, Incorporated engages in the automating, digitizing, and transforming the way people bank and shop worldwide. It operates through two segments, Banking and Retail. The company offers cash recyclers and dispensers, intelligent deposit terminals, teller automation tools, and kiosk technologies, as well as physical security solutions; and front-end applications for consumer connection points and back-end platforms that manage channel transactions, operations and integration, and facilitate omnichannel transactions, endpoint monitoring, remote asset management, customer marketing, merchandise management, and analytics.
Featured Articles
- Five stocks we like better than Diebold Nixdorf
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Health Care Stocks Explained: Why You Might Want to Invest
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is a buyback in stocks? A comprehensive guide for investors
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Diebold Nixdorf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diebold Nixdorf and related companies with MarketBeat.com's FREE daily email newsletter.